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Viral respiratory infections in CF patients are associated with an increase in morbidity at short and long term. Viral infections have a
greater impact on CF patients compared to non-CF controls. They result in increased respiratory symptoms, deterioration of Shwachman and
radiological scores, prolonged hospitalizations, a persistent decrease of pulmonary function, increased use of antibiotics and a higher
frequency of exacerbations at follow-up. In addition, interaction between viruses and bacteria in CF is suggested. Some studies observe
increased new bacterial colonization and raised antipseudomonal antibodies in episodes of viral respiratory infections. Experimental data
suggest that increased virus replication, impaired specific anti-bacterial defense and increased adherence of bacteria play a role in the
pathogenesis of viral respiratory infections in CF. Further knowledge about the role of viruses and interaction with bacteria in CF lung disease
might result in new therapeutic strategies to improve prognosis of CF patients.
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CF is characterized by chronic inflammation, bacterial
colonization and recurrent infections of the lung, resulting in
irreversible deterioration of lung function and early death.
Pseudomonas aeruginosa is one of the most important
pathogens. Chronic colonization of the airways with P.
aeruginosa is associated with progressive and irreversible
lung disease. Besides a constitutive inflammatory state, CF
typically has a course of exacerbations and remissions of
pulmonary complaints, suggesting that external factors
influence this course. Respiratory viruses are known to
cause significant morbidity in infants, elderly and the
immunocompromised. In asthma up to 80% of exacerba-
tions in children are associated with viral infections [1].
In this review, we summarize current knowledge of
epidemiology and clinical impact of viral infections in CF.1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2005.05.011
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pathogenetic role of respiratory viruses in CF pulmonary
disease.2. Clinical studies on viral infections in CF
2.1. Viral epidemiology in CF
Viral infections are often associated with worse
respiratory symptoms in CF patients. In 13–52% of
patients with an increase in respiratory lower tract
symptoms a viral pathogen is detected [2–10], with higher
percentages in younger than in older patients [7]. In 40%
of cases with a pulmonary exacerbation, a virus was
detected, compared to only 9% in those with a stable
clinical condition [2].
Many different viruses are reported (Table 1). Frequen-
cies are influenced by the detection method used by the
individual investigator. Respiratory syncytial virus (RSV)
represents 9–58% of all reported viruses, with the highests 4 (2005) 31 – 36ed by Elsevier B.V. All rights reserved.
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Hiatt PW (’99) 26/150 C,S 21 26 15 15 23% *
Armstrong D (’98) 14/26 I,C 40 27 13 * 20% (13% RV) *
Collinson J (’96) 51/119 P * * * * 100% (41% RV) *
Smyth AR (’95) 44/157 I,C,S,P 9 12 12 9 58% RV *
Pribble CG (’90) 23/80 C,S 14 41 5 * 14% (9% RV) 26% CV
Hordvik NL (’89) 13/35 C,S 15 77 0 * 8% RV *
Ong ELC (’89) 11/92 I,C,S,P 0 27 * 9 55% (45% RV) 9% CMV
Ramsey BW (’89) 98/398 C,S 21 12 29 7 29% (26% RV) 2% HSV
Abman SH (’88) 12/30 I,C 58 0 18 8 8% EV 8% CMV
Wang EL (’84) 105 C,S 23 25 40 12 * *
Petersen NT (’81) 63/332 S 19 24 43 14 * *
I—immunofluorescence; C—culture; S—serology; P— PCR; *—Not mentioned; CMV—cytomegalovirus; EV—enterovirus; CV—coronavirus 229E; RV—
rhinovirus; HSV—herpes simplex virus.
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12–27%, or even up to 77% in one small study [5].
Parainfluenzavirus is found in lower frequencies, only one
study showing a contribution of 43% [7]. Adenovirus is
reported in 8–15% of all viruses. Most studies failed to
detect rhinovirus, probably because the use of serology or
culture. Serology is difficult due to the large number of
rhinovirus subtypes and culture is relatively insensitive.
Polymerase chain reaction (PCR) is up to eleven times more
sensitive to detect rhinoviruses in children [11]. The only
study using PCR demonstrated rhinoviruses in 58% of cases
with respiratory complaints [10]. Other viral agents like
enteroviruses, Epstein Barr virus and cytomegalovirus have
been shown to play a role in CF respiratory symptoms in
low frequencies. Coronavirus was reported only once with a
frequency of 28% [8].
2.2. Clinical impact of viral infections
Viral respiratory infections occur in equal frequency in
CF patients and healthy controls or sibs [4,9,12]. Also, the
frequency of virus infections seems not to be associated
with pre-existing clinical condition [12], although one
study reported a possible association [4]. However, the
clinical impact in CF patients is far beyond the virus-
related morbidity in healthy controls [4,9,12].
In CF patients viral upper respiratory tract infections
are associated with lower respiratory tract symptoms in
31%–76% [5,13]. Respiratory viruses were detected in
40% of patients who needed hospitalization [2,3]. CF
patients were hospitalized for 10–22 days [2,3,12,14],
while none of a matched non-CF control group needed
hospital care [4,12].
Viral infections also cause increased long-term respira-
tory morbidity in CF patients. RSV infection resulted in a
prolonged oxygen need (mean 2.9 months) in 5/7 hospi-
talized young CF children [2]. Several studies demonstrated
a deterioration of Shwachman scores [10,12–14] or radio-logical scores [2,13,14] at long-term follow up after viral
respiratory infections. The severity of deterioration was
related to the frequency of viral respiratory infections
[12,13] or hospitalizations [2]. Patients with virus associated
lower respiratory tract infections had more frequently
pulmonary exacerbations or hospitalizations [6,12,14] and
a higher use of antibiotics [9,10,13] at long-term follow-up,
compared to CF patients without virus associated lower
respiratory tract infections.
2.3. Impact on pulmonary function
Viral respiratory infections in CF patients are associated
with a decline in pulmonary function. Pulmonary function
testing was performed in 9 of 12 clinical studies (Table 2).
FEV1 and FVC declined after virus associated lower
respiratory tract infection in CF patients >6 years
[6,10,12,13]. High frequency of viral upper respiratory tract
infections was associated with a large decline of FEV1 and
FVC [13]. Only one study showed no effect on FVC or RV/
TLC [9].
A persistent decline of pulmonary function after viral
infections was also found in CF patients <6 years [4]. There
was a decline in V’maxFRC and a rise in FRC, especially
after RSV infection. V’maxFRC increased during follow-up
in healthy controls and CF children with upper respiratory
tract symptoms, but deteriorated in CF children with lower
respiratory tract infections.
2.4. Conclusion clinical studies
Viruses are frequently isolated in CF patients with
respiratory symptoms. The frequency and distribution of
respiratory viruses are similar in CF patients and controls.
RSV, influenza virus, parainfluenzavirus and adenovirus are
the most frequently reported, but other viruses may be
underreported for technical reasons. Viral respiratory
infections in CF patients are associated with an increase
Table 2
Outcome data in clinical studies relating viral infections in CF patients
Author Pulmonary function testing URTI Shwachman score Radiologic score Hospitalization Antibiotics
Hiatt PW FRC, V’maxFRC Yes Yes Brasfield Yes No
Armstrong D No No No No Yes Yes
Collinson J FVC, FEV1 (>6 yr) Yes Yes Chrispin-Norman Yes Yes
Smyth AR FVC, FEV1 Yes Yes Chrispin-Norman No Yes
Winnie GB FVC, FEV1 No Yes Brasfield Yes No
Pribble CG FVC, FEV1, FEF25, PEF Yes Yes Brasfield Yes No
Hordvik NL PEF (daily), FVC, FEV1, FEF25-75 No No No No No
Ong ELC No Yes No No No No
Ramsey BW FVC, FEV1, FEF25-75, TLC, RV, RV/TLC No Yes No No Yes
Abman SH No Yes No Brasfield Yes No
Wang EL FVC, FEV1, FEF25-75, TLC, RV, RV/TLC Yes Yes Brasfield Yes Yes
Petersen NT No Yes No No Yes No
URTI—upper respiratory tract infection.
*—Not mentioned.
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respiratory symptoms, deterioration of Shwachman and
radiological scores, prolonged hospitalizations, increased
use of antibiotics and a higher frequency of exacerbations at
follow-up. In contrast to healthy controls, viral infections
often result in a persistent decrease of pulmonary function in
CF patients.3. Bacterial–viral interaction in CF
3.1. Clinical studies
The airways of most young children with CF are
colonized with Haemophilus influenzae and Staphylococcus
aureus. With increasing age pseudomonal colonization
varies from 42% to 100% [4,6,8–10,13,14], with additional
Burkholderia cepacia colonization in older patients
[6,8,10]. In just a few patients no bacteria are detectable.
Several data from clinical studies suggest interaction
between viruses and bacteria in CF.
In 60–68% of cases new bacterial colonization is found
during the viral season [15]. New bacterial colonization
predominantly occurs within 3 weeks after a viral upper
respiratory tract infection [13]. More specifically, 85% of
new pseudomonal colonizations followed a viral upper
respiratory tract infection within 3 weeks [13]. In 35% of
patients who were hospitalized for a viral lower respiratory
tract infection pseudomonal colonization was noticed within
12–60 months [3].
In 11–47% of patients with intermittent or chronic
colonization a viral infection is followed by a rise in
antipseudomonal antibodies [7]. The strongest association
between a viral infection and rise in antipseudomonal
antibodies was found after RSV infection. Twenty percent
of all patients who developed chronic pseudomonal
colonization had a previous RSV infection, compared to
7% of those who did not [7].3.2. Experimental data on mechanisms
Experimental data on the effects of viral infections in CF
are scarce.
Some studies suggest higher virus replication and
impairment of the innate host defense in CF. Intrapulmonary
influenza virus titres were significantly increased in mice
with chronic P. aeruginosa infection, compared to control
mice [16]. Increased virus replication was also found after
parainfluenza virus infection of CF human airway epithelial
cells, compared to controls [17]. Increased virus replication
might explain the more severe and prolonged symptoms
during viral infections in CF patients compared to healthy
controls.
One of the possible causes of increased virus
replication and of virus persistence might be a reduced
production of respiratory nitric oxide (NO), which is an
important part of the innate antiviral defense. Increased
production of NO protects against viral infections [18].
In CF patients expression of the NO producing enzyme
NO synthase type 2 (NOS2) is considerably decreased,
while the IFN-g-dependant antiviral host defense is
intact.
An aberrant immune response to viral infections has also
been found in other chronic respiratory illnesses, like
asthma [19,20]. It might be suggested that repeated viral
infections lead, in the presence of an aberrant immune
response, to an increased virus replication and hyper-
inflammation with increasing symptoms and pulmonary
damage.
Viral infections might also facilitate infections with
colonizing bacteria in patients with CF. Viral infections
cause destruction of the epithelial barrier with loss of
cilia and loss of tight junctions. This results in
increased permeability and exposure of the respiratory
basement membrane, leading to increased possibilities
for bacteria to bind [21]. Bacterial adherence to virus
infected cells is enhanced because bacteria can use
B.E. van Ewijk et al. / Journal of Cystic Fibrosis 4 (2005) 31–3634viral glycoproteins and other virus induced receptors
on the host cell membrane as bacterial receptors [22–
24].
A few studies suggest that viral infection leads to
modulation of the immune response, impairing specific
anti-bacterial defense [25–27]. In a chronic P. aerugi-
nosa infected mouse model fatal pneumonia was
induced by pneumococcal infection following influenza
virus infection. In the absence of the virus the mice
survived the pneumococcal superinfection [16]. Influenza
infection caused a significant increase in inflammatory
cells and cytokine release, and suppressed neutrophil
function.
Earlier data suggest interaction between specific viruses
and bacteria in CF. Influenza virus seems to play a role in
the adherence of P. aeruginosa to respiratory epithelial
cells. Uninfected and influenza-infected murine tracheas
were exposed to six different strains of P. aeruginosa. All
of the strains adhered to desquamating cells of the infected
trachea, but not to normal mucosa or regenerating
epithelium [28].
In summary, experimental data suggest increased virus
replication in CF which can result in severe pulmonary
damage and which can facilitate infections with bacteria
colonizing the CF lungs. More data, especially in the human
model, are necessary to further elucidate the role of viruses
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Fig. 1. Overview of clinical and experimental d4. Implications
Further knowledge about the role of viruses in CF lung
disease might result in new therapeutic strategies to improve
prognosis of patients with CF.
Prevention of viral infections in patients with CF might
be reached by active or passive immunization. At present,
annual influenza vaccination is advised to all CF patients,
although there are some doubts about its effectiveness
[4,9,29,30]. Passive immunization against RSV can be
performed with paluvizumab, but data on effectiveness in
CF patients are lacking. Active vaccination against RSV in
CF patients is in development [31].
Another strategy might be inhibition of virus replication.
Effective antiviral agents are available. Amantadine [32],
zanamivir [33] and oseltamavir [34] can be used against
influenza virus infection. Treatment with oseltamavir
improved survival from 0% to 75% in a mouse model of
secondary pneumococcal pneumonia after influenza virus
infection, even when therapy was delayed for up to 5 days
after influenza virus infection [35]. Ribavirine can possibly
be used against RSV [36] and plecoranil against picorna-
viruses [37]. Beside these specific virus inhibitors, there is
some indication that interferon [17] and statins [38] can
interfere with virus replication.
Influencing the interaction between viruses and bacteria
could be a next pathway to diminish respiratory morbidity infections in CFF
espiratory symptoms
hospitalization
deterioration of Shwachman score
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ata on viral respiratory infections in CF.
B.E. van Ewijk et al. / Journal of Cystic Fibrosis 4 (2005) 31–36 35CF patients. Low-threshold use of antibiotics during viral
infections in patients with CF might prevent secondary
bacterial infections, but data are lacking. Further knowledge
about specific interaction between viruses and bacteria
might lead to development of new therapeutic options.
Up until now, there is no evidence for most suggested
options in general, or more specifically in CF. Efforts should
be made to design studies exploring these options.References
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